4505 EMPEROR BOULEVARD, DURHAM, NC
Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Stockholders Approve Amendment to BioCryst Stock Incentive Plan
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Annual Report to Security Holders
Reports Full Year 2025 Financial Results and Provides Business Update
Amended material disclosure
Material Contracts, Completing Asset Acquisition or Sale, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Reg. FD
FY 2024
Q3
Q2
Q1
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Prospectus Filed Pursuant to Rule 425
S-4
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
SEC Staff Correspondence